ResMed Inc. (ASX:RMD)

Australia flag Australia · Delayed Price · Currency is AUD
40.77
+0.18 (0.44%)
Sep 26, 2025, 4:12 PM AEST
15.30%
Market Cap 60.27B
Revenue (ttm) 7.85B
Net Income (ttm) 2.14B
Shares Out n/a
EPS (ttm) 14.51
PE Ratio 28.21
Forward PE 24.72
Dividend 0.50 (1.24%)
Ex-Dividend Date Aug 13, 2025
Volume 758,776
Average Volume 1,194,341
Open 41.01
Previous Close 40.59
Day's Range 40.70 - 41.15
52-Week Range 32.04 - 45.25
Beta 0.85
RSI 40.25
Earnings Date Oct 23, 2025

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]

Sector Healthcare
Founded 1989
Employees 10,600
Stock Exchange Australian Securities Exchange
Ticker Symbol RMD
Full Company Profile

Financial Performance

In 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.

Financial numbers in USD Financial Statements

News

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, RMD, VRT and NFG are some such stocks.

4 days ago - Nasdaq

ResMed (RMD) Receives 'Buy' Rating from Citigroup with $330 Price Target | RMD Stock News

ResMed (RMD) Receives 'Buy' Rating from Citigroup with $330 Price Target | RMD Stock News

10 days ago - GuruFocus

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present...

11 days ago - GlobeNewsWire

The sleep economy is 'having a moment', says medical equipment firm Resmed

Carlos Nunez, Chief Medical Officer of Resmed takes about the opportunities and challenges in the sleep economy with CNBC's Martin Soong. He joins 'Squawk Box Asia' on the sidelines of the World Sleep...

19 days ago - CNBC International TV

The sleep economy is 'having a moment', says medical equipment firm Resmed

Carlos Nunez, Chief Medical Officer of Resmed takes about the opportunities and challenges in the sleep economy with CNBC's Martin Soong. He joins 'Squawk Box Asia' on the sidelines of the World Sleep...

20 days ago - CNBC

Top 50 High-Quality Dividend Stocks For September 2025

I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto...

21 days ago - Seeking Alpha

ResMed Inc (RMD) Launches Global Initiative to Revolutionize Sleep Health Care | RMD stock news

ResMed Inc (RMD) Launches Global Initiative to Revolutionize Sleep Health Care | RMD stock news

24 days ago - GuruFocus

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care New global clinical insights initiative debuts at World Sleep Congress 2025 to...

24 days ago - GlobeNewsWire

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the public...

4 weeks ago - GlobeNewsWire

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also ann...

5 weeks ago - GlobeNewsWire

How Resmed’s Mick Farrell turned a $7b company into a $62b giant

Family business successions are often a disaster. At ResMed, the global sleep device manufacturer, it has proven to be a winning formula.

7 weeks ago - The Australian Financial Review

Top 50 High-Quality Dividend Stocks For August 2025

My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated futur...

7 weeks ago - Seeking Alpha

ResMed RMD Q4 2025 Earnings Call Transcript

7 weeks ago - The Motley Fool

Nasdaq 100 and S&P500: Tech and Healthcare Stocks Lead US Indices Higher Today

US stocks rebound as weak jobs data boosts Fed rate cut hopes; tech and healthcare sectors lead gains, with Tesla, Spotify, and ResMed in focus.

7 weeks ago - FX Empire

ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings

Resmed Inc (NYSE: RMD) reported better-than-expected earnings for the second quarter on Thursday . The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate o...

2 months ago - Benzinga

ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings

Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday.

2 months ago - Benzinga

ResMed declares $0.60 dividend

2 months ago - Seeking Alpha

ResMed (RMD) Reports Strong Q4 2025 Results, Announces Dividend Increase

ResMed (RMD) Reports Strong Q4 2025 Results, Announces Dividend Increase

2 months ago - GuruFocus

Resmed beats forecasts as annual sleep device sales hit $8b

The California-based company plans to ramp up investment, increase dividends and improve profit margins in the year ahead.

2 months ago - The Australian Financial Review

Resmed beats quarterly profit estimates on strong demand for sleep devices

Resmed beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea.

2 months ago - Reuters